Autologous stem cell transplantation (ASCT) is a widely used therapeutic option in first-line treatment of multiple myeloma. However, many patients eventually relapse.
Medical oncologist Hani Hassoun reviews a study that examined patterns of post-ASCT relapse. Evidence-based recommendations for optimal surveillance of patients are discussed.
